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leavage of membrane-anchored heparin-binding EGF-
like growth factor (proHB-EGF) via metalloprotease
activation yields amino- and carboxy-terminal regions
(HB-EGF and HB-EGF-C, respectively), with HB-EGF widely
recognized as a key element of epidermal growth factor
receptor transactivation in G protein–coupled receptor
signaling. Here, we show a biological role of HB-EGF-C in
cells. Subsequent to proteolytic cleavage of proHB-EGF,
HB-EGF-C translocated from the plasma membrane into
C
 
the nucleus. This translocation triggered nuclear export of
the transcriptional repressor, promyelocytic leukemia zinc
ﬁnger (PLZF), which we identify as an HB-EGF-C binding
protein. Suppression of cyclin A and delayed entry of S-phase
in cells expressing PLZF were reversed by the production
of HB-EGF-C. These results indicate that released HB-EGF-C
functions as an intracellular signal and coordinates cell
cycle progression with HB-EGF.
 
Introduction
 
Interreceptor cross-talk has received significant attention
recently as an essential element in understanding the increas-
ingly complex signaling networks identified within cells.
Transactivation of the epidermal growth factor receptor
(EGFR) has been shown to play a crucial role in the signaling
by G protein–coupled receptors (GPCRs), cytokine receptors,
receptor tyrosine kinases, and integrins to a variety of cellular
responses (Hackel et al., 1999; Moghal and Sternberg,
1999). Transactivation of EGFR is mediated, at least in
some cases, by the EGFR ligand heparin-binding EGF-like
growth factor (HB-EGF), which is cleaved from its membrane-
anchored form (proHB-EGF) in a process termed “ecto-
domain shedding” (Prenzel et al., 1999).
The proHB-EGF molecule is proteolytically cleaved by
“a disintegrin and metalloprotease” (ADAM) 9, 12, 10, or
17 (Izumi et al., 1998; Asakura et al., 2002; Lemjabbar and
Basbaum, 2002; Sunnarborg et al., 2002; Yan et al., 2002)
to release a soluble form of HB-EGF. This cleavage can
be stimulated by treating cells with various agents, includ-
ing the phorbol ester 12-
 
O
 
-tetradecanoylphorbol-13-acetate
(TPA), an activator of PKC (Goishi, et al., 1995). Recent
analyses have shown that the processing of proHB-EGF by
metalloproteases plays important roles in cutaneous wound
healing (Tokumaru et al., 2000) and branching morphogen-
esis of the submandibular gland (Umeda et al., 2001). Fur-
thermore, the cleavage of proHB-EGF is required for EGFR
transactivation by GPCR signaling (Prenzel et al., 1999),
which is involved in various biological processes such as cardiac
hypertrophy (Asakura et al., 2002), cystic fibrosis (Lemjab-
bar and Basbaum, 2002), and the mitogenic effects of
arachidonic acid metabolites (Chen et al., 2002; Cussac et
al., 2002).
Although much has been learned about the functions of
extracellular domains produced by ectodomain shedding,
very little attention has been paid to the remnant cell-associated
domains also created by the processing event. Here, we focus
on a biological role played by the carboxy-terminal remnant
(HB-EGF-C) produced in parallel with HB-EGF, and
characterize it as a novel intracellular signaling molecule
acquired posttranslationally. Using fluorescent protein–tagged
proHB-EGF and an antibody recognizing the cytoplasmic
region of proHB-EGF, we visualized the translocation of
HB-EGF-C from the plasma membrane into the nucleus
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after ectodomain shedding of proHB-EGF. Yeast two-
hybrid screening resulted in the cloning of an HB-
EGF-C binding protein, promyelocytic leukemia zinc finger
(PLZF), previously identified as a transcriptional repressor
and a negative regulator of the cell cycle. The proteolytic
release of HB-EGF-C via metalloprotease activation caused
nuclear export of PLZF and reversal of cyclin A suppression
and delayed entry of S-phase by PLZF in human fibrosar-
coma HT1080 cells. Intracellular trafficking of endogenous
HB-EGF-C into the nucleus and the subsequent nuclear ex-
port of PLZF after metalloprotease processing of proHB-
EGF were also observed in human primary cultured kerati-
nocytes. Thus, our present data provide new insights into
the inter- and intracellular communication generated by
proHB-EGF processing.
 
Results
 
Translocation of HB-EGF-C after 
TPA-inducible processing
 
To investigate the behavior of HB-EGF-C after metallopro-
tease processing of proHB-EGF, we constructed an expres-
sion vector encoding a protein in which YFP was fused to
the carboxy terminus of proHB-EGF (HB-EGF–YFP). This
vector was then transfected into human fibrosarcoma
HT1080 cells. HB-EGF–YFP was localized at the plasma
membrane of the transfected cells and its ectodomain was re-
leased by TPA-inducible proteolysis, as shown previously
with wild-type proHB-EGF (unpublished data). In trans-
fected cells treated with TPA for 60 min, fluorescent images
revealed the translocation and accumulation of HB-EGF–
YFP around the nucleus (Fig. 1, A and B). Time-lapse imag-
ing showed that HB-EGF–YFP began to internalize and ac-
cumulate in the cytoplasm 15 min after TPA stimulation,
and that a majority of the fluorescent protein had disap-
peared from the plasma membrane and was observed within
the cytoplasm 30 min after TPA stimulation (Fig. 1 C).
Next, we examined the localization of HB-EGF-C by sep-
arating cytoplasmic and nuclear fractions from HT1080
cells overexpressing proHB-EGF (HT1080/HB-EGF cells).
We used an antibody recognizing the cytoplasmic region of
proHB-EGF (#H1) to detect proHB-EGF and HB-EGF-C.
 
Figure 1.
 
Translocation of HB-EGF-C after TPA-inducible processing.
 
 
(A–C) HT1080 cells were transiently transfected with a plasmid 
encoding the fusion protein HB-EGF–YFP, in which YFP was fused 
to the carboxy terminus of proHB-EGF. After 24 h, the subcellular 
localization of the YFP sequence was visualized with fluorescent 
microscopy. (A) HB-EGF–YFP in unstimulated cells was observed 
at the plasma membrane. After stimulation with 100 nM TPA for 
60 min, HB-EGF–YFP was absent from the plasma membrane, 
but detected in the cytoplasm and localized around the nucleus. 
(B) Localization of the fusion protein was confirmed by confocal 
microscopy. (C) Representative time-lapse images of HB-EGF–YFP 
transfected cells are shown every 5 min for up to 55 min after TPA 
treatment. Note that HB-EGF–YFP at the plasma membrane was 
translocated into the cytoplasm after TPA stimulation of the cells. 
(D and E) Accumulation of HB-EGF-C in the nucleus of HT1080 
cells overexpressing proHB-EGF (HT1080/HB-EGF cells). (D) Cyto-
plasmic (Cyto.) and nuclear (Nuc.) fractions were prepared from 
HT1080/HB-EGF cells (2.0 
 
 
 
 10
 
7
 
). After the incubation with or without 
TPA for 30 min, cells were lysed and immunoblotted using anti-HB-
EGF-C antibody (#H1). In addition to a 25-kD band (proHB-EGF), 
the 6.7-kD band (HB-EGF-C) was detected in the cytoplasmic fraction 
when cells were treated with TPA. The 6.7-kD band was also detect-
able in the nuclear fraction after TPA stimulation. (E) Accumulation 
of HB-EGF-C after TPA treatment was also observed by immunofluo-
rescence microscopy using the #H1 antibody. (F) Transient expres-
sion of the amino-terminally FLAG-tagged dominant-negative form 
of presenilin-1 (D385A) was not altered HB-EGF–YFP translocation 
after TPA treatment in HT1080 cells (left). Expression of the FLAG-
tagged presenilin-1 mutant was confirmed by immunoblotting with 
anti-FLAG antibody (right, arrow). Bars, 10 
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A large amount of proHB-EGF was accumulated in the cy-
toplasmic fraction, and the band of HB-EGF-C was not ob-
served in cytoplasmic and nuclear fractions without the
stimulation (Fig. 1 D). After TPA treatment for 30 min, the
6.7-kD band (the expected size of an HB-EGF-C with
transmembrane and cytoplasmic domains of proHB-EGF)
was detectable in both cytoplasmic and nuclear fractions of
HB-EGF-C after TPA treatment (Fig. 1 E).
To test whether 
 
 
 
-secretase activity is involved with the
proteolytic release of HB-EGF-C, we investigated the effect
of a dominant-negative mutant of presenilin-1 (PS1 D385A),
which reduces 
 
 
 
-secretase activity (Wolfe et al., 1999), on
HB-EGF-C translocation after TPA treatment. Transient ex-
pression of amino-terminally FLAG-tagged dominant-nega-
tive PS1 in HT1080 cells was not altered the HB-EGF–YFP
translocation induced by TPA treatment (Fig. 1 F).
 
Identification of PLZF as a proHB-EGF 
cytoplasmic domain–binding protein
 
The translocation of HB-EGF-C after proHB-EGF pro-
cessing suggested that after proHB-EGF processing, HB-
EGF-C could interact with cytoplasmic or nuclear proteins.
To identify potential binding proteins of HB-EGF-C, we used
yeast two-hybrid cloning and screened a human heart
cDNA library using the cytoplasmic region of proHB-EGF
(residues 185–208) as bait. Screening of 10
 
6
 
 transformants
yielded 16 positive clones. One of the clones (referred to as
clone 3) encoded a carboxy-terminal sequence of PLZF pro-
tein (Fig. 2 A), a transcriptional repressor that is localized in
the nucleus (Chen et al., 1993; Reid et al., 1995). Immuno-
precipitation from COS cells expressing proHB-EGF and
CFP-tagged PLZF (CFP-PLZF) revealed that CFP-PLZF
was coimmunoprecipitated with the #H1 antibody once the
cells were treated with TPA (Fig. 2 B).
To determine the region of PLZF that interacts with HB-
EGF-C, we performed a GST pull-down assay. Various FLAG-
tagged PLZF derivatives (Fig. 2 C) were incubated with glu-
tathione Sepharose beads containing recombinant HB-EGF-C
fused to GST (GST–HB-EGF-C). In agreement with the data
obtained from the yeast study, the zinc finger region containing
nine zinc finger motifs (the carboxy terminus of PLZF protein)
interacted with GST–HB-EGF-C (Fig. 2 D). We further char-
acterized the zinc finger region of PLZF required for interac-
tion with HB-EGF-C. GST–HB-EGF-C pulled down zinc
finger 5
 
 
 
8 motifs (Zn5
 
 
 
8) efficiently and zinc finger 1
 
 
 
6
motifs (Zn1
 
 
 
6) partially, but not the zinc finger 6
 
 
 
7 motifs
(Zn6
 
 
 
7; Fig. 2 E). However, deletion of Zn6
 
 
 
7 abrogated
the binding of PLZF to GST–HB-EGF-C (Fig. 2 F). These
data suggest that the Zn6
 
 
 
7 region is essential and Zn5
 
 
 
8 is
sufficient for the PLZF-HB-EGF-C interaction.
 
Nuclear export of PLZF triggered by TPA-inducible 
ectodomain shedding of proHB-EGF
 
Next, we examined the subcellular localization of PLZF by
using the expression vector encoding CFP-PLZF. This ex-
pression vector was transfected into four types of cell lines as
follows: HT1080 cells; a stable transfectant of HT1080 ex-
pressing proHB-EGF (HT1080/HB-EGF); a stable dou-
ble  transfectant of HT1080 cells expressing proHB-EGF
and a metalloprotease domain–deleted mutant of ADAM12
(HT1080/
 
 
 
MP-ADAM12/HB-EGF); and a stable transfec-
tant of HT1080 expressing an uncleavable mutant (L148G;
Hirata et al., 2001) of proHB-EGF (HT1080/HB-EGF-
UC). Endogenous HB-EGF expression was very low in pa-
rental HT1080 cells (unpublished data).
CFP-PLZF was predominantly localized in the nucleus in
HT1080 cells and in the three transfectants. TPA treatment
did not alter the subcellular localization of CFP-PLZF in
HT1080 cells. In contrast, TPA treatment for 60 min dis-
tributed CFP-PLZF in the entire cytoplasm of HT1080/
HB-EGF cells (Fig. 3 A). A previous experiment had re-
vealed that ADAM12 can mediate HB-EGF shedding, and
that expression of a dominant-negative (metalloprotease do-
main–deleted mutant) form of ADAM12 inhibited proHB-
EGF processing in HT1080 cells (Asakura et al., 2002).
In HT1080/
 
 
 
MP-ADAM12/HB-EGF cells, the export of
CFP-PLZF from the nucleus to the cytoplasm was not ob-
served after TPA stimulation. Similarly, HT1080/HB-EGF-
UC cells did not show the nuclear export of CFP-PLZF de-
spite TPA treatment (Fig. 3 A). Quantitative analyses (see
Materials and methods) verified that the number of cells
with nuclear-localized CFP-PLZF was reduced by the TPA
treatment in HT1080/HB-EGF cells, but not in parental
HT1080 cells, HT1080/
 
 
 
MP-ADAM12/HB-EGF cells, or
HT1080/HB-EGF-UC cells (Fig. 3 C).
Proteolytic cleavage of proHB-EGF induced by TPA yields
at least two fragments, HB-EGF and HB-EGF-C. Therefore,
we next investigated whether EGFR activation by HB-EGF
was involved in triggering the nuclear export of CFP-PLZF in
HT1080/HB-EGF cells. HT1080/HB-EGF cells transfected
with the plasmid encoding CFP-PLZF were preincubated
with 10 
 
 
 
g/ml of EGFR-neutralizing antibody (an amount of
antibody sufficient to inhibit tyrosine phosphorylation of
EGFR in HT1080/HB-EGF cells after TPA addition; unpub-
lished data). Nuclear export of CFP-PLZF by TPA stimula-
tion was still observed in the presence of the antibody (Fig. 3,
B and D). On the other hand, by pretreatment with 10 
 
 
 
M
KB-R7785, a metalloprotease inhibitor that blocks proHB-
EGF processing by ADAM12 (Asakura et al., 2002), the fre-
quency of the nuclear export of CFP-PLZF after TPA stimula-
tion of HT1080/HB-EGF cells was reduced (Fig. 3, B and D).
The export of CFP-PLZF was also inhibited by preincubation
of the cells with 10 ng/ml leptomycin B (LMB), a specific in-
hibitor of CRM1 (designated exportin 1)-dependent nuclear
export (Kudo et al., 1999; Fig. 3, B and D). These results indi-
cate that generation of HB-EGF-C by proHB-EGF processing
is required for the nuclear export of PLZF.
The GST pull-down analysis indicated that deletion of
Zn6
 
 
 
7 of PLZF abrogated the binding to HB-EGF-C. There-
fore, we investigated the nuclear export of CFP-PLZF with de-
letion of Zn6
 
 
 
7 (CFPPLZF
 
 
 
Zn6
 
 
 
7) in HT1080/HB-EGF
cells. The frequency of the CFP-PLZF
 
 
 
Zn6
 
 
 
7 export much
decreased as compared with CFP-PLZF after TPA stimulation
(Fig. 3, E and F). This result indicates that binding of PLZF to
HB-EGF-C is essential for the nuclear export of PLZF.
 
Translocation and interaction of HB-EGF-C with PLZF 
precedes nuclear export of PLZF
 
Next, we performed the simultaneous visualization of
proHB-EGF processing and PLZF transport. Processing ofT
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Figure 2. Identification of PLZF as an HB-EGF-C binding protein. (A) We used the yeast two-hybrid method and screened a human heart 
cDNA library with the cytoplasmic region of HB-EGF (HB-EGF-Cyto; residues 185–208) as bait. One of the positive clones (clone 3) was 
identified as encoding a portion of PLZF. (B) COS cells were transiently transfected with a proHB-EGF expression vector and a CFP-PLZF 
expression vector encoding a fusion protein in which CFP was fused to the amino terminus of PLZF, stimulated for 60 min with TPA, and lysed. 
Expression of CFP-PLZF was confirmed by immunoblotting of the whole lysate with anti-GFP antibody (lane 1). The lysates were immuno-
precipitated with anti-HB-EGF-C antibody (#H1), and the precipitates were immunoblotted with anti-GFP antibody (lanes 2 and 3). Note that 
the interaction between PLZF and HB-EGF was observed when cells were stimulated with TPA. (C–F) GST pull-down assay. Cell lysates 
containing the FLAG-tagged PLZF derivatives were incubated with GST (1) or GST–HB-EGF-C (2) beads, and bound proteins were detected 
by immunoblotting using an anti-FLAG antibody (right). Expression of the derivatives was also confirmed by immunoblotting using an anti-FLAG 
antibody (left). (C) Schematic diagrams of FLAG-tagged PLZF derivatives. Nine zinc finger motifs in the PLZF protein are numbered from first 
to ninth. Binding properties of PLZF derivatives to GST–HB-EGF-C is summarized in the right lane of each structure. The binding properties 
are based on the estimation from the intensity of bands as compared with the control band and are indicated as    ( 50%),   (50–10%), 
and   ( 10%). (D) Full-length PLZF and the fragment containing nine zinc finger motifs (Zn Finger) were bound to GST–HB-EGF-C, but not 
to GST alone. (E) The fragments consisting of zinc finger motifs 4 9 (Zn4 9) and 5 8 (Zn5 8) were bound to GST–HB-EGF-C stronger than 
the fragment with zinc finger motifs 1 6 (Zn1 6). The fragment consisting of zinc finger motifs 6 7 (Zn6 7) was not efficient for the interaction. 
(F) Deletion mutant ( Zn6 7) showed that the region with Zn6 7 was essential for HB-EGF-C–PLZF interaction.T
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Figure 3. Processing of proHB-EGF by ADAM12 causes nuclear export of PLZF. Subcellular localization of CFP-PLZF fusion protein in 
HT1080 cells and its variants. The CFP-PLZF expression vector was transiently transfected into four types of cells: HT1080 cells (HT1080); 
proHB-EGF–overexpressing HT1080 cells (HT1080/HB-EGF); proHB-EGF– and metalloprotease domain–deleted mutant of ADAM12-
overexpressing HT1080 cells (HT1080/ MP-ADAM12/HB-EGF); and uncleavable-type proHB-EGF–overexpressing HT1080 cells (HT1080/
HB-EGF-UC). (A and C) 24 h after the transfection, CFP-PLZF was predominantly localized at the nucleus in these four cell types. In HT1080/
HB-EGF cells (but not the other types of cells), CFP-PLZF was distributed in the entire cytoplasm after treatment of the cells with 100 nM TPA 
for 60 min (B and D). A metalloprotease inhibitor KB-R7785 (10  M), but not an EGFR-neutralizing antibody (10  g/ml), inhibited nuclear export 
of CFP-PLZF in HT1080/HB-EGF cells in response to treatment with TPA for 60 min. Note that nuclear export of CFP-PLZF was dependent on 
the processing of HB-EGF, but that EGFR signaling was not involved in this process. 10 ng/ml leptomycin B (LMB), a specific inhibitor of 
CRM1-dependent nuclear export, also inhibited nuclear export of CFP-PLZF after TPA treatment. (E and F) The expression vectors encoding 
CFP-PLZF (CFP-PLZF) or Zn6 7 deletion mutant of CFP-PLZF (CFP-PLZF Zn6 7) were transiently transfected into HT1080/HB-EGF cells. 
After 24 h, changes in subcellular localization of CFP-tagged proteins after TPA treatment were examined. Note that the export of CFP-PLZF Zn6 7 
was suppressed in HT1080/HB-EGF cells after TPA stimulation. Bars, 10  m.T
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HB-EGF–YFP did not promote nuclear export of PLZF
(unpublished data), possibly due to the fused YFP interfer-
ing with the interaction between HB-EGF-C and PLZF.
Therefore, HB-EGF–YFP and CFP-PLZF expression vec-
tors were cotransfected into HT1080/HB-EGF or HT1080/
 
 
 
MP-ADAM12/HB-EGF cells that stably expressed wild-
type proHB-EGF. Images were collected every 15 min up to
90 min after TPA treatment. In HT1080/HB-EGF cells, in-
ternalization of HB-EGF–YFP was observed 30 min after
the treatment, but nuclear export of CFP-PLZF did not oc-
cur until 45 min after TPA stimulation (Fig. 4 A). In
HT1080/
 
 
 
MP-ADAM12/HB-EGF cells, subcellular local-
ization of HB-EGF–YFP and CFP-PLZF were not changed
despite TPA treatment (Fig. 4 B).
Time course–dependent changes in interactions of HB-
EGF-C with CFP-PLZF were investigated in these cells by
immunoprecipitation experiments. Anti-HB-EGF-C anti-
body #H1 clearly coimmunoprecipitated CFP-PLZF at 15
min and the later with maximal binding at 30 and 75 min
after TPA stimulation in HT1080/HB-EGF cells, but not in
Figure 4. Nuclear export of PLZF follows internalization of HB-EGF-C. (A and B) Time-lapse imaging of CFP-PLZF and HB-EGF–YFP in living 
cells. Cells cotransfected with CFP-PLZF and HB-EGF–YFP expression vectors were cultured for 24 h before observation, and then the culture 
medium was replaced with medium containing 100 nM TPA. Shown are representative serial images of transfected HT1080/HB-EGF (A) and 
HT1080/ MP-ADAM12/HB-EGF (B) cells taken every 15 min up to 90 min after TPA stimulation. Note that translocation of HB-EGF–YFP 
preceded nuclear export of CFP-PLZF in HT1080/HB-EGF cells. Changes in subcellular localization of the CFP and YFP fusion proteins were 
not observed after TPA treatment of HT1080/ MP-ADAM12/HB-EGF cells. (C) Time course–dependent changes in interaction of HB-EGF-C 
with CFP-PLZF. The HB-EGF-C–PLZF interaction was investigated by immunoprecipitation using an anti-HB-EGF-C antibody in HT1080/HB-EGF 
and HT1080/ MP-ADAM12/HB-EGF cells. The band of CFP-PLZF coimmunoprecipitated with HB-EGF-C (top) was evident at 15 min and 
the later after TPA treatment in HT1080/HB-EGF but not HT1080/ MP-ADAM12/HB-EGF cells, despite same expression of CFP-PLZF in cells 
(bottom). Bars, 10  m.T
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HT1080/
 
 
 
MP-ADAM12/HB-EGF cells (Fig. 4 C). These
results, together with time-lapse images, indicate that inter-
nalized HB-EGF-C interacted with nuclear PLZF.
 
The proHB-EGF cytoplasmic region is required 
for PLZF transport
 
The data presented in Fig. 3 indicated that proteolytic release
of HB-EGF-C by proHB-EGF processing could trigger the
nuclear export of PLZF. Therefore, we designed three types of
cytoplasmic deletion mutants of proHB-EGF (HB
 
 
 
C10,
HB
 
 
 
C19, and HB
 
 
 
C22; Fig. 5 A), constructed their expres-
sion vectors, and established stable transfectants of HT1080
cells with each of the vectors. All YFP-tagged deletion
mutants of proHB-EGF were also localized at the plasma
membrane and internalized into the cytoplasm by TPA treat-
ment (unpublished data). HT1080/HB
 
 
 
C10 cells (as well
as HT1080/HB-EGF cells) showed TPA-responsible nu-
clear export of PLZF. However, in HT1080/HB
 
 
 
C19 and
HT1080/HB
 
 
 
C22 cells, nuclear export of PLZF did not oc-
cur despite TPA stimulation (Fig. 5, B and C).
 
Increased expression of cyclin A and promotion 
of S-phase progression associated with nuclear 
export of PLZF
 
It has been reported that PLZF is a transcriptional repressor
of cyclin A and inhibits cell growth (Shaknovich et al.,
1998; Yeyati et al., 1999). HT1080/HB-EGF cells trans-
fected with an expression vector for FLAG-tagged PLZF
(FLAG-PLZF) were cultured for 48 h in the medium con-
taining 3% serum, and then the culture medium was re-
placed with fresh medium with and without 100 nM TPA.
After 8 h, expression of both FLAG-PLZF and cyclin A was
examined by immunofluorescence microscopy. The inten-
sity of cyclin A immunofluorescence in the transfected cells
expressing FLAG-PLZF (Fig. 6 A, arrows) was much less
than that in untransfected cells (Fig. 6 A, arrowheads). TPA
treatment distributed FLAG-PLZF into the entire cyto-
plasm and up-regulated the immunofluorescence intensity
of cyclin A in the transfected cells (Fig. 6 A, arrows) to the
same level as that in the untransfected cells (Fig. 6 A; ar-
rowheads). The range of relative fluorescence intensity of
cyclin A in TPA-treated cells was narrower than that in
nontreated cells, and the reduced expression of cyclin A as-
sociated with nuclear-localized FLGA-PLZF was not ob-
served (Fig. 6 B). However, in HT1080, HT1080/
 
 
 
MP-
ADAM12/HB-EGF, and HT1080/HB-EGF-UC cells,
FLAG-PLZF was localized in the nucleus and suppressed
cyclin A expression in the absence or presence of TPA (un-
published data).
The effect of PLZF on cell cycle was investigated in
HT1080 and HT1080/HB-EGF cells. To control cell cycle
progression and proHB-EGF processing simultaneously, we
synchronized the cells infected with the PLZF or LacZ ex-
pression adenoviruses in G0/G1-phase by serum depriva-
tion, and then stimulated the cells back into cycle by addi-
tion of 10% serum. proHB-EGF processing is induced by
serum-containing medium without any particular stimuli
(Goishi et al., 1995; Hirata et al., 2001), and a large amount
of released HB-EGF was detected in the conditioned me-
dium of HT1080/HB-EGF cells (unpublished data). After
the serum stimulation, the cells were collected every 4 h up
to 24 h and analyzed for DNA content and cyclin A expres-
Figure 5. Cytoplasmic region of proHB-EGF is required for PLZF export after TPA stimulation. (A) Structures of cytoplasmic deletion mutants 
of proHB-EGF. These mutants, HB C10, HB C19, and HB C22, were truncated by 10, 19, and 22 amino acids, respectively, from the carboxy 
terminus of proHB-EGF. (B and C) Subcellular localization of CFP-PLZF in HT1080 cells stably expressing proHB-EGF and its cytoplasmic 
deletion mutants. CFP-PLZF was predominantly localized in the nucleus in these stable transfectants. In HT1080/HB-EGF and HT1080/HB C10 
cells, TPA treatment distributed CFP-PLZF to the entire cytoplasm. However, in HT1080/HB C19 and HT1080/HB C22 cells, the export of 
CFP-PLZF from nucleus was not observed after TPA stimulation. Bar, 10  m.T
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sion by flow cytometry and immunoblotting, respectively.
Entrance into S-phase was delayed in the PLZF-expressing
HT1080 cells compared with the control LacZ-expressing
HT1080 cells (Fig. 6, C and D). Consistent with the delay
of S-phase entry, increased expression of cyclin A after the
stimulation was suppressed in HT1080 cells expressing
PLZF (Fig. 6 D). However, S-phase entry and cyclin A regu-
lation were reversed in HT1080/HB-EGF cells expressing
PLZF (Fig. 6, C and D).
 
Intracellular localization of HB-EGF-C in human 
keratinocyte cell line HaCaT and primary 
cultured cells
 
We examined human keratinocyte cell line HaCaT and pri-
mary cultured cells to determine the localization of endoge-
nous HB-EGF-C. TPA treatment of HaCaT cells (Fig. 7 A)
as well as primary cultured cells (unpublished data) resulted
in the production of an 
 
 
 
6.7-kD band, the expected size of
an HB-EGF-C retaining both the transmembrane and cyto-
Figure 6. Processing of proHB-EGF reverses PLZF-dependent cyclin A suppression and delayed entry of S-phase. (A and B) Expression analysis 
of FLAG-PLZF and cyclin A by immunofluorescence microscopy. An expression vector encoding FLAG-tagged PLZF (FLAG-PLZF) was transiently 
transfected into HT1080/HB-EGF cells, and the expression of FLAG-PLZF and cyclin A was detected with anti-FLAG and anti-cyclin A antibodies, 
respectively. (A) In transfected cells (arrows), FLAG-PLZF was localized at the nucleus and suppressed cyclin A expression in the absence of 
TPA treatment. In the presence of TPA, FLAG-PLZF was distributed into the entire cytoplasm, and the expression level of cyclin A in the 
transfected cells (arrows) was the same as that in the untransfected cells (arrowheads). (B) Relative fluorescence intensity of cyclin A and FLAG-PLZF 
was measured at the nucleus of the transfected cells. (C and D) Cell cycle analysis by DNA staining and cyclin A immunoblotting. HT1080 
cells and its variants infected with PLZF or LacZ (control) expression adenoviruses were synchronized in G0/G1-phase by serum deprivation for 
36 h and were restimulated into cell cycle with 10% serum. At the indicated times, cells were collected and analyzed for cell cycle phase and 
cyclin A expression. (C) Exogenous expression of PLZF by adenovirus induced the delay of S-phase entry after the serum stimulation in HT1080, 
but not in HT1080/HB-EGF cells. Cells were stained with propidium iodide and analyzed by FACS
® to determine their DNA content and cell 
cycle phase at 0 and 8 h after addition of 10% serum. Cell number is plotted on the y axes, and DNA content is plotted on the x axes. (D) The 
delay of S-phase entry and suppression of cyclin A expression were reversed by proHB-EGF processing. The percentage of cells in S-phase is 
plotted versus time after serum stimulation. Whole-cell lysates from HT1080 and HT1080/HB-EGF cells (10
5) harvested at each point were 
immunoblotted with anti-cyclin A antibody. The expression of  -actin was examined as a control (not depicted). Bar, 10  m.T
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plasmic domains of proHB-EGF. HB-EGF-C was in the
Golgi apparatus after 30 min of TPA treatment, as deter-
mined by its colocalization with the Golgi protein p115
(Nelson et al., 1998; Fig. 7 B). HB-EGF-C accumulated and
partially colocalized with FLAG-tagged PLZF at the nucleus
of HaCaT cells after 60 min of TPA treatment (Fig. 7 C).
Gene expression of PLZF was detected by RT-PCR in hu-
man primary keratinocytes, but not in HT1080 or HaCaT
cells (unpublished data). Immunostaining of endogenous
HB-EGF-C, PLZF, and cyclin A in primary cultured kerati-
nocytes revealed their complemental localization in nucleus,
cytoplasm, and plasma membrane under different condi-
tions (Fig. 8 A). Keratinocytes in culture medium supple-
mented with bovine brain extracts showed heterogeneous
staining of HB-EGF-C, PLZF, and cyclin A. However, TPA
treatment clearly localized HB-EGF-C in nuclei and PLZF
in the cytoplasm (Fig. 8, A and B). On the other hand, KB-
R7785 treatment mainly localized HB-EGF at the plasma
membrane and PLZF in the nuclei despite the addition of
TPA (Fig. 8 A). Cyclin A was detected in the nuclei of most
cells in response to the nuclear export of PLZF (Fig. 8 A).
Increased expression of cyclin A in cultured keratinocytes af-
ter proHB-EGF processing was also confirmed by immuno-
blotting (Fig. 8 C). Further, treatment with angiotensin
II,  which causes GPCR-mediated EGFR transactivation
through proHB-EGF processing in keratinocytes (unpub-
lished data), also triggered the localization of HB-EGF-C in
nuclei and PLZF in the cytoplasm, which was canceled ef-
fectively by the addition of KB-R7785 (Fig. 8 D).
Immunoprecipitation of PLZF in primary cultured kerati-
nocytes resulted in the coprecipitation of HB-EGF-C, and the
amount of the coprecipitated HB-EGF-C increased when the
cells were incubated with TPA before lysis (Fig. 8 E). Thus,
the interaction between PLZF and HB-EGF-C also occurs in
primary cells. Similarly, anti-HB-EGF-C antibody #H1 also
coimmunoprecipitated PLZF in the same cells (Fig. 8 E).
 
PLZF-HB-EGF-C interaction in vivo
 
We also examined the interaction of PLZF and HB-EGF-C
in vivo using a TPA-treated mouse skin model of kerati-
nocyte hyperplasia. TPA treatment of mouse skin tissue for
24 and 48 h produced keratinocyte hyperplasia as reported
previously (Hawighorst et al., 2001; Fig. 9 A). Immuno-
precipitation of PLZF in the homogenates of TPA-treated
and control mouse skin tissues resulted in the coprecipita-
tion of a 6.7-kD band recognized by anti-HB-EGF-C anti-
Figure 7. Characterization of endogenous HB-EGF-C in HaCaT cells. (A) Characterization of endogenous HB-EGF-C in untransfected 
HaCaT cells. 10
8 HaCaT cells that had been incubated in the presence or absence of TPA were lysed and immunoprecipitated with an 
HB-EGF-C antibody #H1, and the precipitates were immunoblotted with antibodies #H1 or #H6 (recognizing HB-EGF ectodomain). Both 
antibodies detected the 20–30-kD heterogenous bands of proHB-EGF. A 6.7-kD band was detected with the #H1 antibody, but not with #H6, 
and the density of this band was enhanced by TPA treatment. The apparent size of this band was consistent with the putative size of a form of 
HB-EGF-C containing the transmembrane and cytoplasmic domains of proHB-EGF. (B) Staining with the #H1 antibody showed that the cell 
surface HB-EGF–associated fluorescence was reduced once untransfected HaCaT cells were treated with TPA for 30 min. The perinuclear 
accumulation of HB-EGF-C, more evident after TPA treatment for 30 min, was colocalized with p115, a marker protein of the Golgi apparatus. 
(C) The plasmid encoding FLAG-PLZF was transiently transfected into HaCaT cells, and after 48 h, the localization of FLAG-PLZF and endogenous 
HB-EGF-C was visualized with immunofluorescent microscopy. HB-EGF-C accumulated and partially colocalized with FLAG-PLZF at the 
nucleus of HaCaT cells after 30 min of TPA treatment. Bars, 10  m.T
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Figure 8. Interaction and traffic of endogenous HB-EGF-C and PLZF in human primary cultured keratinocytes. (A) Detection and localization 
of endogenous HB-EGF-C, PLZF, and cyclin A in primary human cultured keratinocytes by immunofluorescence microscopy. Keratinocytes 
were cultured in medium supplemented with bovine brain extracts and stained with antibodies against HB-EGF-C, PLZF, and cyclin A. 
Heterogeneous staining of HB-EGF-C, PLZF, and cyclin A was observed under the normal culture conditions. However, TPA treatment 
clearly localized HB-EGF-C in nuclei and PLZF in the cytoplasm, and up-regulated the expression of cyclin A in nuclei. KB-R7785 treatment 
resulted in HB-EGF-C staining at the plasma membrane and PLZF staining in nuclei despite the addition of TPA. (B) Nuclear accumulation 
of HB-EGF-C and export of PLZF after TPA stimulation. To facilitate the changes in subcellular localization of HB-EGF-C and PLZF after 
TPA treatment, we performed a nuclear staining using Hoechst 33258 in combination with immunostaining using anti-HB-EGF-C or PLZF. 
(C) Analysis of cyclin A expression in primary human cultured keratinocytes by immunoblotting. Consistent with immunostaining data, 
increased expression of cyclin A was observed in the keratinocytes treated with TPA. KB-R7785 suppressed cyclin A expression despite TPA 
stimulation. The expression of  -actin was examined as a control. (D) Staining of HB-EGF-C in nuclei and PLZF in the cytoplasm was 
also observed after angiotensin II treatment of the cells for 6 h, and this effect was reversed by the addition of KB-R7785 to the medium. 
(E) Interaction of HB-EGF-C and PLZF in human primary cultured keratinocytes. Cell lysates (10
7 cells) were immunoprecipitated with anti-PLZF 
antibody and immunoblotted with anti-PLZF (top left) and HB-EGF-C #H1 (bottom left) antibodies. Coimmunoprecipitated HB-EGF-C was 
slightly detectable in lysates from cells in normal culture conditions (lane 1), but the intensity of this band was increased by TPA treatment 
(lane 2). Addition of KB-R7785 (lane 3) resulted in the loss of the HB-EGF-C from the PLZF immunoprecipitates. Anti-HB-EGF-C antibody 
#H1 also coimmunoprecipitated PLZF (top right; each lane indicates the same condition as in left panel). PLZF was equally present in each 
cell lysate, as shown by Western blotting (bottom right). Bars, 10  m.T
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body #H1 in TPA-treated tissue homogenates alone (Fig. 9
B), suggesting that the PLZF-HB-EGF-C interaction oc-
curs in vivo.
Discussion
The biological functions of the EGFR ligand HB-EGF, shed
by proteolytic cleavage from the amino terminus of the
transmembrane proHB-EGF, have been well studied. In
contrast, roles of the carboxy-terminal fragment (HB-EGF-
C) produced by proHB-EGF processing have not been pre-
viously investigated. Our present work has three major find-
ings concerning HB-EGF-C. First, HB-EGF-C generated
by ectodomain shedding of proHB-EGF is translocated
from the plasma membrane to the nucleus. Second, the pro-
teolytic release of HB-EGF-C results in nuclear export of the
transcriptional repressor PLZF. Third, cell cycle regulation
by nuclear PLZF is reversed by proHB-EGF processing.
Figure 9. Involvement of the HB-EGF-C–PLZF interaction in epidermal hyperplasia. In vivo interaction between HB-EGF-C and PLZF in 
TPA-treated mouse skin hyperplasia. (A) Mouse skin was treated with TPA, and keratinocyte hyperplasia was successively observed for 48 h 
by HE staining. (B) The homogenates of TPA-treated and control mouse skin tissues were immunoprecipitated with anti-PLZF antibody and 
immunoblotted with anti-PLZF (top) or HB-EGF-C #H1 (bottom) antibodies. A 6.7-kD band identified as HB-EGF-C was detected in TPA-treated 
tissue homogenates, but not in control skin tissues. Bar, 10  m.
Figure 10. Schematic models of the roles of HB-EGF-C. (A) An intracellular signaling mediated by HB-EGF-C produced by proHB-EGF 
processing. (B) Coordination of cell cycle progression by shed HB-EGF and HB-EGF-C.T
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Using the technology of fluorescent proteins, we first
demonstrated that HB-EGF-C was internalized into the cy-
toplasm after ectodomain shedding. Immunoblotting of the
nuclear fraction and immunostaining using the antibody
recognizing the cytoplasmic region of proHB-EGF (#H1)
revealed the accumulation of endogenous HB-EGF-C in the
nucleus after the processing. The 6.7-kD band of HB-EGF-C
and no effect of dominant-negative presenilin-1 on HB-
EGF-C translocation indicate that HB-EGF-C has the
proHB-EGF transmembrane domain and is not further pro-
cessed by  -secretase. The colocalization of HB-EGF-C with
p115, a marker protein of the Golgi apparatus, indicates that
it is internalized by vesicular trafficking. Although the de-
tailed transport mechanism of HB-EGF-C containing trans-
membrane domain remains unclear, recent analyses of nu-
clear localization of receptor tyrosine kinases raise the
possibility that the Golgi–ER pathway is a route to the nu-
cleus of type I transmembrane molecules (Carpenter, 2003).
As shown in Fig. 1, TPA treatment localized HB-EGF–YFP
around the nucleus, but not in the nucleus. HB-EGF–YFP
did not promote the nuclear export of PLZF after TPA
treatment (unpublished data). Therefore, we speculate that
the YFP moiety fused to the carboxy terminus of HB-EGF-C
might aggregate and fail to enter the nucleus, which abro-
gates the HB-EGF-C–PLZF interaction.
Recently, it has been reported that neuregulin-1 is cleaved
at the transmembrane domain and the released intracellular
domain (Nrg-1-ICD) enters the nucleus to repress expres-
sion of several regulators of apoptosis (Bao et al., 2003). Bao
et al. (2003) also mentioned that Nrg-1-ICD forms the
complex with a second zinc finger–containing protein re-
lated to PLZF. Although the machinery of carboxy-terminal
signaling of proHB-EGF and neuregulin-1 seems to be dif-
ferent, these results, together with our present data, suggest
that the carboxy-terminal fragments of the EGF family pre-
cursors are functional molecules that control gene expression
by regulating transcription factors in the nucleus.
It is apparent that nuclear accumulation of HB-EGF-C,
nuclear export of PLZF, and interaction between HB-EGF-C
and PLZF are mutually exclusive. Although the machin-
ery of this signaling is still unclear, one possible mechanism
suggested by time course–dependent changes in the interac-
tion and localization of HB-EGF-C and PLZF is as follows:
(1) HB-EGF-C is translocated into the nucleus after proHB-
EGF processing; (2) HB-EGF-C associates with nuclear
PLZF; and (3) PLZF is exported from the nucleus in a
CRM1-dependent manner (Fig. 10 A).
The cleavage of proHB-EGF is required for EGFR trans-
activation in response to GPCR signaling (Prenzel et al.,
1999, Asakura et al., 2002, Chen et al., 2002; Cussac et al.,
2002; Lemjabbar and Basbaum, 2002), suggesting that post-
translational processing of proHB-EGF is involved in a vari-
ety of biological processes. In the present report, we show
that nuclear export of PLZF also results from angiotensin II
stimulation in human primary cultured keratinocytes. This
result suggests that proHB-EGF processing by the GPCR
signaling cascade leads to the nuclear export of PLZF. PLZF
is expressed in a large number of tissues, and perinatal up-
regulation of this factor is observed in the kidney, liver, and
heart (Cook et al., 1995; Reid et al., 1995). PLZF produces
transcriptional repression through recruitment of a repressor
complex that contains N-CoR, SMRT, Sin3a, and histone
deacetylase (Hong et al., 1997; David et al., 1998; Grignani
et al., 1998; Guidez et al., 1998; He et al., 1998; Lin et al.,
1998). The study of PLZF knockout mice indicates that
PLZF represses Hox gene expression though chromatin re-
modeling to regulate the patterning of limb and axial skele-
ton, and is involved in apoptosis and cell proliferation dur-
ing limb development (Barna et al., 2000, 2002). Thus,
these findings suggest potential roles for HB-EGF-C medi-
ated nuclear export of PLZF and the subsequent effects on
regulation of cell proliferation and Hox gene expression in
various signaling cascades during the development and
maintenance of adult tissues.
It has been reported that PLZF is a transcriptional repres-
sor of cyclin A and suppresses cell growth by inhibiting entry
or progression of S-phase in the cell cycle (Shaknovich et al.,
1998; Yeyati et al., 1999). Gene expression control by tran-
scriptional regulators occurs in the nucleus, and nuclear ex-
port of these factors results in loss of the regulation. The
present data show that HB-EGF-C generated by ecto-
domain shedding of proHB-EGF causes nuclear export of
PLZF, increases the expression of cyclin A, and promotes
S-phase entry. Furthermore, the interaction of HB-EGF-C
and PLZF occurs in the TPA-treated mouse skin model of
keratinocyte hyperplasia. On the other hand, proHB-EGF
processing also generates HB-EGF, a soluble ligand of
EGFR. It is well known that HB-EGF activates EGFR sig-
naling and promotes G1-phase progression in the cell cycle
by regulating the expression of cyclin D via the Ras-MAPK
signaling cascade (Hackel et al., 1999; Prober and Edgar,
2001). Therefore, our current paper suggests that proHB-
EGF has two functional domains affecting mitogenic signal-
ing. Posttranslational processing of proHB-EGF by metallo-
protease activation produces intercellular and intracellular
signaling molecules simultaneously (Fig. 10 A). The coordi-
nation of the resulting dual mitogenic signals may be impor-
tant for cell cycle progression in various signaling cascades
(Fig. 10 B).
Materials and methods
Plasmid construction
A plasmid for recombinant expression of YFP-tagged proHB-EGF was gen-
erated by subcloning the human HB-EGF cDNA with the stop codon de-
leted into pEYFP-N1 (CLONTECH Laboratories, Inc.). A plasmid for recom-
binant expression of CFP-tagged PLZF was generated by subcloning the
human PLZF cDNA into pECFP-C1 (CLONTECH Laboratories, Inc.). DNA
fragments encoding the deleted cytoplasmic region of proHB-EGF with or
without stop codon were generated by PCR and substituted for the corre-
sponding region in pEYFP-N1-HB-EGF. A plasmid encoding FLAG-tagged
PLZF was generated by subcloning the FLAG sequence and the human
PLZF cDNA into pcDNA3.1 (Invitrogen). pcDNA3.1/FLAG/PS1(D385A)
was a gift from Dr. Okochi (Osaka University, Osaka, Japan). Plasmids for
recombinant expression of FLAG-tagged PLZF derivatives were generated
by subcloning the FLAG and various PLZF derivative sequences made by
PCR into pME18S. A plasmid for recombinant expression of GST-fused
HB-EGF-C was generated by subcloning the HB-EGF-C sequence made by
PCR into pGEX6P-1 (Amersham Biosciences). All cDNA constructs were
verified by DNA sequencing.
Yeast two-hybrid assay
The cytoplasmic domain of proHB-EGF (residues 185–208; Higashiyama et
al., 1991) was used to screen a human heart cDNA library in the yeast two-T
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hybrid assay, following the manufacturer’s instructions for the Match-
maker™ two-hybrid assay system (CLONTECH Laboratories, Inc.). About
10
6 transformants were screened, and library plasmids from 16 positive
clones were analyzed by transformation tests and DNA sequencing (Gietz et
al., 1992).  -Galactosidase activity was measured by liquid and filter assays.
Cellular fractionation, immunoprecipitation, 
and immunoblotting
Cytoplasmic and nuclear fractions were prepared using the CellLytic Nu-
Clear extraction kit (Sigma-Aldrich). Immunoprecipitation and immuno-
blotting of cell lysates was performed as described previously (Goishi et
al., 1995). Primary antibodies were used as follows: mouse monoclonal
IgG antibodies to FLAG (Sigma-Aldrich), PLZF (Oncogene Research Prod-
ucts), and cyclin A (Neomarkers); rabbit pAbs to GFP (MBL International
Corporation), and HB-EGF-C (#H1) and HB-EGF (#H6) (Miyagawa et al.,
1995). Secondary antibodies were HRP-conjugated goat anti–mouse and
anti–rat IgG (Promega).
GST pull-down assay
GST and GST–HB-EGF-C were expressed in and purified from the Esche-
richia coli BL21 strain according to standard protocol. After binding of
GST and GST–HB-EGF-C to the glutathione Sepharose beads, cell lysates
containing various FLAG-tagged PLZF derivatives were incubated with 20
 l of the beads for 2 h at 4 C. After being washed, bound proteins were an-
alyzed by immunoblotting using anti-FLAG antibody (Sigma-Aldrich).
Cell lines and transfection
HT1080/HB-EGF and HT1080/ MP-ADAM12/HB-EGF cells were de-
scribed previously (Asakura et al., 2002). For the establishment of HT1080/
HB-EGF-UC or HT1080/HB C cells, the plasmids encoding uncleavable-
type proHB-EGF, HB C mutants were introduced into HT1080 cells using
LipofectAMINE™ 2000 (Life Technologies), and stably transfected clones
were isolated. HT1080 cells and its transfectants were grown in MEM sup-
plemented with nonessential amino acids (Life Technologies), 10% FBS,
and antibiotics. COS and HaCaT cells were maintained in DME containing
10% FBS. The culture of primary human keratinocytes was as described
previously (Hashimoto et al., 1994). All cells were cultured in a humidified
37 C/5% CO2 incubator.
For transient transfections, 4.0   10
5 cells were seeded per 35-mm cell
culture dish (Corning), grown for 12 h in the respective medium, and then
transfected with expression vectors using LipofectAMINE™ 2000 (Life
Technologies).
Imaging of YFP or CFP fusion proteins
Transiently transfected cells were cultured for 24 h and then used for exper-
iments. For treatment with the EGFR-neutralizing antibody (Upstate Bio-
technology), KB-R7785 (Asakura et al., 2002), or leptomycin B (Sigma-
Aldrich), the cells were incubated in serum-free medium with 10  g/ml
antibody for 2 h, 10  M KB-R7785 for 30 min, or 10 ng/ml leptomycin B
for 2 h, and then cultured in the same medium containing 100 nM TPA for
1 h. Subcellular localization of YFP or CFP fusion proteins was examined
under an epifluorescence microscope (Eclipse TE300; Nikon) (Fig. 1, A and
F, Fig. 3, and Fig. 5). Time-lapse observations were made with the same
epifluorescence microscope with a stage incubator (Fig. 1 C and Fig. 4).
Quantitation of the fraction of cells 
with nuclear-localized CFP-PLZF
To quantitate the fraction of cells in a population that displayed predomi-
nantly nuclear localization of CFP-PLZF, fields of cells were scored using a
completely blind manner. The cells expressing CFP-PLZF were categorized
into two classes: those in which CFP-PLZF was predominantly localized in
the nucleus (N), and those in which CFP-PLZF was distributed throughout
the entire cytoplasm (C). The ratio of the number of cells with nuclear CFP-
PLZF among total transfected cells (N/[N   C]   100) was then calculated
to generate the percentage of cells with nuclear-localized CFP-PLZF. This
ratio was found to be in good agreement with the qualitative impression of
microscopic observations. The values (means   SD) were determined
based on the results obtained in at least two independent transfections,
and at least 200 independent cells expressing CFP-PLZF were examined in
each experiment.
Immunofluorescence microscopy
Cells were fixed in 4% PFA in PBS at 4 C for 10 min and permeabilized for
10 min in 0.2% Triton X-100 in PBS. Cells were blocked with 1% BSA,
and subsequently incubated at RT with primary and secondary antibodies.
Primary antibodies were used as follows: mouse monoclonal IgG antibod-
ies to FLAG (Sigma-Aldrich), PLZF (Oncogene Research Products), and cy-
clin A (Neomarkers); a rabbit pAb to HB-EGF-C (#H1), and a goat pAb to
p115 (Santa Cruz Biotechnology, Inc.). Secondary antibodies were used
as follows: FITC- and rhodamine-conjugated goat anti–mouse IgG,
rhodamine-conjugated goat anti–rat IgG, FITC-conjugated goat anti–rabbit
IgG (CHEMICON International), and Alexa
® Fluor 568–conjugated donkey
anti–goat IgG (Molecular Probes, Inc.). Some cells were also stained with
Hoechst 33258 (Molecular Probes, Inc.). Stained cells were viewed with
an epifluorescence microscope (Eclipse TE300; Nikon) (Fig. 1 E, Fig. 6, and
Fig. 7) or a confocal microscope (model LSM 510; Carl Zeiss Micro-
Imaging, Inc.) (Fig. 1 B and Fig. 8). The thickness of optical sections was
0.8  m.
Adenovirus vector construction and infection
Adenovirus vectors carrying genes encoding PLZF and LacZ were prepared
using the adenovirus expression vector kit (Takara Biomedicals). Purified,
concentrated, and titer-checked viruses were infected to the cells at a mul-
tiplicity of infection of 50.
Cell cycle analysis
For DNA staining, cells were fixed in 70% ethanol for 2 h at 4 C and incu-
bated with 0.25 mg/ml RNase for 1 h at 37 C. After being washed, cells
were stained with 0.05 mg/ml propidium iodide. Data acquisition was per-
formed with a FACScan™ (Becton Dickinson) flow cytometer. Cell cycle
distribution was analyzed with ModFit software (Nippon Becton Dickin-
son).
TPA treatment of mouse skin
200  l of 0.1 mM TPA, dissolved in acetone, was applied topically to the
shaved back skin of 20-wk-old female C57/BL6 mice every 24 h. After 24
or 48 h, skin samples were harvested as an 8-mm punch biopsy and stored
at   80 C until use. For immunoprecipitation, protein was extracted in
1,000  l lysis buffer with protease inhibitors using a polytron homoge-
nizer.
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